LONDON (Reuters) – AstraZeneca expects to return to growth faster than analysts currently predict after a wave of drug patent expiries, with 2017 revenue likely to be broadly in line with the 2013 level.
The forecast marks a bid by the drugmaker to call a bottom to a sales decline that is being driven by loss of exclusivity on top-selling medicines, including Nexium for excess stomach acid, which loses U.S. patent cover this year.
LONDON, Jan 13 (Reuters) – GlaxoSmithKline has
handed back rights to an experimental drug for Duchenne muscular
dystrophy to U.S.-listed Dutch biotech firm Prosensa
after it failed last year in a critical clinical trial.
Both companies said on Monday that Prosensa would now have
full and unencumbered rights to drisapersen, as well as other
compounds at an earlier stage of development. The move marks the
termination of a 2009 collaboration deal between the two firms.
LONDON, Jan 8 (Reuters) – AstraZeneca has raised its
bet on new treatments that harness the body’s immune system to
fight cancer by striking a drug development deal with private
British biotech company Immunocore.
Bristol-Myers Squibb, Roche and Merck & Co
lead the field with such immunotherapies, which analysts
believe may extend patients’ lives significantly and generate
tens of billions of dollars in annual sales.